As a sequel to last week's paper on the fundamentals of clinical trial design, this paper tackles related controversial issues: noninferiority trials, the value of factorial designs, the importance and challenges of strategy trials, Data Monitoring Committees (including when to stop a trial early), and the role of adaptive designs. The standard approach to designing a noninferiority trial is to pre-define a noninferiority margin, commonly called delta, for the primary endpoint. This is the smallest treatment difference, which, if true, would mean that the new treatment is declared inferior. This is on the basis of the belief that any difference smaller than this would constitute clinically accepted grounds of "therapeutic interchangeability" (4). The trial's conclusions then depend on where the 95% confidence interval (CI) for
This review explores challenging issues that may arise and builds on the fundamentals of trial design covered in last week's paper.
Specifically, we offer guidance on how to design and interpret noninferiority trials where the goal is to demonstrate that the efficacy of a new treatment is as good as that achieved with a standard treatment.
Factorial trials, where 2 (or more) therapeutic issues are simultaneously evaluated in the same study, present an interesting opportunity that should be considered more often in cardiology research.
Trials that compare substantially different alternative treatment strategies can be of great value in enhancing good patient management, and we present guidance on the topic to stimulate greater interest in overcoming the difficulties in undertaking such pragmatic studies.
All major cardiology trials have both ethical and practical needs for data monitoring of the accumulating evidence over time. We provide insights into how Data
Monitoring Committees (DMCs) should function, offering statistical guidelines and practical decisionmaking considerations as to when to stop a trial early.
Finally, there is a growing interest in adaptive designs, but few instances of their implementation in cardiology trials. We focus on adaptive sample size re-estimation and enrichment strategies, with guidance on when and how they may be used.
All of these issues are illustrated by experiences from actual cardiology trials, demonstrating the realworld implications of trial design decisions.
NONINFERIORITY TRIALS
Increasingly, major trials are conducted to see if the efficacy of a new treatment is as good as a standard treatment (1) (2) (3) . The new treatment usually has some other advantage (e.g., fewer side effects, ease of administration, lower cost), making it worthwhile to demonstrate noninferiority in respect to efficacy.
The standard approach to designing a noninferiority trial is to pre-define a noninferiority margin, commonly called delta, for the primary endpoint. This is the smallest treatment difference, which, if true, would mean that the new treatment is declared inferior. This is on the basis of the belief that any difference smaller than this would constitute clinically accepted grounds of "therapeutic interchangeability" (4) . The trial's conclusions then depend on where the 95% confidence interval (CI) for the treatment difference ends up in relation to this margin. If the upper bound of the 2-sided 95% CI is less than delta, one can claim evidence that the new treatment is noninferior. A common misunderstanding is that lack of a statistically significant difference between 2 therapies implies that they are equivalent. For instance, the
INSIGHT (Intervention as a Goal in Hypertension
Treatment) trial compared nifedipine with coamilozide in hypertension. The authors concluded that the treatments were "equally effective in preventing cardiovascular complications," on the basis of a p value of 0.35 for the primary composite endpoint of cardiovascular (CV) death, MI, heart failure, or stroke (6) . But, the observed relative risk of 1.10 had a 95% CI of 0.91 to 1.34. This includes up to a 34% excess risk on nifedipine, making it unwise to conclude that nifedipine is as good as (i.e., noninferior to) co-amilozide. This example raises a few issues. When the noninferiority margin is a difference in percentages, it becomes easier (perhaps too easy) to achieve noninferiority if the overall event rate is lower than expected. The OPTIMIZE trial had an anticipated 9% event rate in the control arm, but the observed event rate was 6%.
This made the 2.7% margin equivalent to a relative risk margin of 1.45, which is undesirably large.
Conversely, if the overall event rate is greater than expected, it may become unreasonably difficult to achieve noninferiority. The opposite considerations of anticipated versus observed event rates apply if a relative risk is chosen for the margin.
Also, the endpoint chosen in the OPTIMIZE trial was not of optimal relevance. The true issue in considering a shorter period of dual antiplatelet treatment concerns the balance between the increased risks of stent thrombosis and MI against the reduced risk of major bleeding. To force these diverse endpoints into a single composite would bias results toward the null. A preferable approach is to prespecify and study separately-powered efficacy and safety endpoints, typically 1 for superiority and 1 for noninferiority. However, a very large sample size may be required to adequately power both the efficacy and safety endpoints.
A composite net adverse clinical events endpoint, consisting of combined safety and efficacy endpoints, has been used in some trials, reflecting the recognition that both types of endpoints (e.g., major bleeding and stent thrombosis) are deleterious and strongly associated with subsequent mortality. However, interpretation of such a combined safety and efficacy endpoint may be challenging, especially if the different components do not have similar effects on patients' well-being or survival. Moreover, because safety and efficacy endpoints often move in different directions (e.g., in response to more potent antithrombotic therapies), their combination in a composite endpoint may mask differences between therapies, making careful examination of each component measure essential.
A key question is the choice of noninferiority margin, which has implications for the required trial size. Power calculations for noninferiority trials (not 
presented here) indicate that trial size is inversely proportional to the square of the margin delta. For instance, had ACUITY chosen a 10% increase, rather than a 25% increase (i.e., relative risk 1.1, rather than 1.25), more than 6Â as many patients would have been required for the same power (i.e., >50,000 in total). Thus, the choice of margin requires a realistic balancing of scientific goals with an achievable sample size.
The choice of margin is sometimes related to prior knowledge of the efficacy of the active control compared with placebo. A sensible goal is that the new treatment should preserve at least 50% of the effect demonstrated in prior trials of the control treatment against placebo (the so-called "putative In addition to the assumed event rates, margin, and desired power, the sample size of a noninferiority trial depends on whether the delta will be tested against the upper bound of a 1-or 2-sided 95% CI (the latter being equivalent to a 1-sided 97.5% confidence limit). The latter conservative approach is the standard for regulatory approval of new pharmaceuticals (and many devices). However, some devices, such as the FilterWire EX system (Boston Scientific, Marlborough, Massachusetts) to prevent distal embolization during percutaneous coronary intervention (PCI) of diseased saphenous vein grafts, which was examined in the FIRE (FilterWire EX Randomized Evaluation) trial (9) , have been approved on the basis of a noninferiority design with a 1-sided alpha of 5%.
Utilizing a 1-sided alpha of 5%, rather than 2.5%, analysis, rather than analysis by intention-to-treat, thereby excluding any follow-up after a patient 
FACTORIAL DESIGNS
Sometimes, one can pursue 2 separate treatment comparisons within the same major trial by randomizing each patient twice: once to treatment A versus its control, and at the same time, to treatment B and its control. This is known as a 2-way factorial design (13, 14) . Factorial designs have numerous practical benefits, such as adding in a second randomization within the framework of a trial funded for a different purpose, affording the opportunity to investigate an inexpensive treatment that would otherwise be difficult to fund and test in its own trial. For instance, the HOPE (Heart Outcomes Prevention Evaluation) factorial trial studied ramipril versus placebo and then also vitamin E versus its placebo in high-risk patients (15, 16) . Ramipril significantly reduced CV events, whereas vitamin E did not.
In planning a factorial design, one presumes that the treatment effect in 1 randomized comparison is not likely to depend on the other randomized treatment: that is, there is no expectation of an interaction between the 2 randomized treatments. Thus, the trial is powered to examine the main effects of the 2 randomized comparisons separately. By doing so, one neatly gets "2 trials for the price of 1"; that is, in principle adding in the second randomization does not increase the trial size. In practice, it may be wise to somewhat inflate trial size when a factorial design is contemplated because: 1) if both treatments are effective, the overall event rate will be lower; and 2) one may wish to guard against a modest quantitative interaction being present. (26) .
TRIALS OF ALTERNATIVE TREATMENT STRATEGIES
A prior survey of interested cardiologists asked if they would enroll their eligible patients in a randomized trial with a 50% chance of being conservatively managed without cardiac catheterization; 80% responded positively (27) . The ISCHEMIA trial initially planned to recruit 8,000 patients, but after more than 2 years, only w2,000 patients have been randomized, which may require a protocol amendment to reduce the sample size. Such lower-thandesired recruitment is a common problem with strategy trials.
Pocock et al. Let us conclude this section with potential stopping guidelines for a planned placebo-controlled trial of a new drug for patients at high CV risk. The trial is to recruit 13,000 patients, and completion is planned when 1,600 primary major adverse CV events have occurred, anticipated to take >5 years duration in total. This gives 90% power to detect a 15% risk reduction (i.e., hazard ratio: 0.85). The trial plans to have 2 interim analyses, after 50% and 75% of primary events have occurred, and the proposed stopping boundaries for superiority and for futility are shown in Table 2 .
First, the timing of these boundaries recognizes that stopping for either superiority or futility should not be contemplated before at least one-half of the trial's evidence has accumulated. The superiority guideline (p < 0.0002) reflects the spirit of only stopping when there is overwhelming evidence. It is interesting to note that to stop early, the hazard ratios for the major adverse CV event primary endpoint at the 2 interim looks would need to be <0.768 and <0.806, respectively, considerably more beneficial than the hazard ratio of 0.85 used in the power calculation. Given the tough stopping boundary, the final p value <0.05 for a positive outcome is not compromised, and with 1,600 primary events, an observed hazard ratio <0.906
would reach statistical significance.
The stopping guidelines for futility in Table 2 are on the basis of conditional power calculations. With 50% of the event data in (800 primary endpoint events), if the hazard ratio is only very slightly in a positive direction (hazard ratio >0.979) or in the CV ¼ cardiovascular; HR ¼ hazard ratio. 
ADAPTIVE DESIGNS
The conventional wisdom in clinical trial design is that once the study protocol is finalized, the trial should Hence, we now concentrate on adaptive sample size re-estimation. The logic is that if the observed treatment difference for the primary endpoint at a preplanned interim analysis is somewhat smaller than that assumed in the original power calculation, trial size may be increased to provide adequate power to detect such a more modest treatment effect. For this approach to be valid, the interim results need to be in a "promising zone," that is: 1) the observed interim treatment difference, although smaller than hoped for, is still trending in the right direction and is big enough to be of clinical relevance; and 2) the expansion in sample size takes the conditional power from a current 50%þ to a desired 80% or higher. Then, the type I error may be preserved without any statistical adjustments.
A sample size increase could also be considered if the effect size is preserved, but the endpoint rates at the interim analysis are lower than anticipated. The promising zone refers to the scenario where the observed difference is less than hoped for, but conditional power can still be raised to the desirable 90% by increasing the sample size. This works fine if the observed difference is at least 66% of the pre-planned difference (point C in Figure 2 ) for which a doubling of size is needed.
One can then extend the promising zone into less optimistic territory, where a doubling is still to be done, even though the conditional power cannot make it to the desired 90%. For instance, point D in It is our hope that this series may help clinical trialists and sponsors to more effectively design studies, statisticians interfacing with study leadership to bring forward the most relevant issues to jointly address, and cardiologists to critically interpret and appraise published studies so as to effectively translate clinical trial evidence to patient care.
